Supernus Pharmaceuticals (SUPN) Treasury Shares (2020 - 2026)
Supernus Pharmaceuticals' (SUPN) quarterly Treasury Shares came in at $355477.0 in Q1 2026, up 79.79% year-on-year from $197720.0 in Q1 2025, and down 8.97% on a QoQ basis from $390496.0 in Q4 2025.
Supernus Pharmaceuticals (SUPN) Treasury Shares (2020 - 2026) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 7 years of Treasury Shares data on file, last reported at $355477.0 in Q1 2026.
- On a quarterly basis, Treasury Shares rose 79.79% year-over-year to $355477.0 in Q1 2026; TTM through Mar 2026 was $355477.0, a 79.79% increase from a year earlier, with the FY2025 full-year figure at $390496.0, up 20.27% from the prior year.
- Treasury Shares for Q1 2026 stood at $355477.0, down from $390496.0 in the prior quarter.
- Over the last five years, Treasury Shares for SUPN reached as high as $427200.0 in Q2 2024 and fell as low as $20000.0 in Q2 2023.
- Historically, Treasury Shares has averaged $278130.4 across 5 years, with a median of $306516.0 in 2023.
- Across the five-year window, Treasury Shares slumped 84.9% in 2023 and surged 2036.0% in 2024, its largest moves.
- Year by year, Treasury Shares stood at $181750.0 in 2022, then surged by 49.45% to $271630.0 in 2023, then advanced by 19.53% to $324685.0 in 2024, then climbed by 20.27% to $390496.0 in 2025, then slipped by 8.97% to $355477.0 in 2026.
- Per Business Quant data, the three most recent Treasury Shares figures were $355477.0 in Q1 2026, $390496.0 in Q4 2025, and $397543.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 62.52 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 107.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.29 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 313.27 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.44 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - | 355,477.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355,477.00 |
| Mar 31, 2026 | 355,477.00 |
| Dec 31, 2025 | 390,496.00 |
| Dec 31, 2025 | 390,496.00 |
| Sep 30, 2025 | 397,543.00 |
| Sep 30, 2025 | 397,543.00 |
| Jun 30, 2025 | 419,216.00 |
| Jun 30, 2025 | 419,216.00 |
| Mar 31, 2025 | 197,720.00 |
| Mar 31, 2025 | 197,720.00 |
| Dec 31, 2024 | 324,685.00 |
| Dec 31, 2024 | 324,685.00 |
| Sep 30, 2024 | 383,300.00 |
| Sep 30, 2024 | 383,300.00 |
| Jun 30, 2024 | 427,200.00 |
| Jun 30, 2024 | 427,200.00 |
| Mar 31, 2024 | 396,908.00 |
| Mar 31, 2024 | 396,908.00 |
| Dec 31, 2023 | 271,630.00 |
| Dec 31, 2023 | 271,630.00 |